Page 269 - Read Online

Qin et al. Hepatoma Res 2020;6:24 I http://dx.doi.org/10.20517/2394-5079.2020.04 Page 15 of 18

T-cell response and effective tumor control. Nat Commun 2019;10:3874.
45. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR et al. Tumor endothelium FasL establishes a selective immune barrier
promoting tolerance in tumors. Nat Med 2014;20:607-15.
+
+
46. Han Y, Chen Z, Yang Y, Jiang Z, Gu Y, et al. Human CD14 CTLA-4 regulatory dendritic cells suppress T-cell response by cytotoxic
T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology
2014;59:567-79.
47. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003;300:337-9.
48. Borst J, Ahrends T, Babala N, Melief CJM, Kastenmuller W. CD4(+) T cell help in cancer immunology and immunotherapy. Nat Rev
Immunol 2018;18:635-47.
49. Benites BD, Alvarez MC, Saad STO. Small particles, big effects: the interplay between exosomes and dendritic cells in antitumor
immunity and immunotherapy. Cells 2019;8:1648.
50. Choi YJ, Park SJ, Park YS, Park HS, Yang KM, et al. EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor
immunity in hepatocellular carcinoma cells. PloS one 2018;13:e0190638.
51. Dou L, Ono Y, Chen YF, Thomson AW, Chen XP. Erratum: hepatic dendritic cells, the tolerogenic liver environment, and liver disease.
Semin Liver Dis 2018;38:298.
52. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013;39:38-48.
53. Sun K, Wang L, Zhang Y. Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma.
Cell Mol Immuno 2006;3:197-203.
54. Chen YX, Man K, Ling GS, Chen Y, Sun BS, et al. A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-
based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10. J Immunol
2007;179:6009-15.
55. Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, et al. Increased levels of interleukin-10 in serum from patients with hepatocellular
carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer
Res 2004;10:7260-9.
56. Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun 2019;10:5408.
57. Peng M, Mo Y, Wang Y, Wu P, Zhang Y, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer 2019;18:128.
58. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
59. Xu M, Zhao Z, Song J, Lan X, Lu S, et al. Interactions between interleukin-6 and myeloid-derived suppressor cells drive the
chemoresistant phenotype of hepatocellular cancer. Exp Cell Res 2017;351:142-49.
60. Guha P, Gardell J, Darpolor J, Cunetta M, Lima M, et al. STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-
derived suppressor cells. Oncogene 2019;38:533-48.
61. Sun H, Yang W, Tian Y, Zeng X, Zhou J, et al. An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and
immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. Nat Commun 2018;9:5214.
62. Li B, Zhang S, Huang N, Chen H, Wang P, et al. CCL9/CCR1 induces myeloidderived suppressor cell recruitment to the spleen in a
murine H22 orthotopic hepatoma model. Oncol Rep 2019;41:608-18.
63. Zhou J, Liu M, Sun H, Feng Y, Xu L, et al. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell
immunosuppression and enhances immune-checkpoint blockade efficacy. Gut 2018;67:931-44.
64. Limagne E, Richard C, Thibaudin M, Fumet JD, Truntzer C, et al. Tim-3/galectin-9 pathway and mMDSC control primary and
secondary resistances to PD-1 blockade in lung cancer patients. Oncoimmunology 2019;8:e1564505.
65. Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, et al. Myeloid derived suppressor cells inhibit natural killer cells
in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 2009;50:799-807.
66. Hu CE, Gan J, Zhang RD, Cheng YR, Huang GJ. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular
carcinoma development by impairing dendritic cell function. Scand J Gastroenterol 2011;46:156-64.
67. Wu CJ, Tsai YT, Lee IJ, Wu PY, Lu LS, et al. Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular
carcinoma through immunomodulation of tumor microenvironment. Oncoimmunology 2018;7:e1477459.
68. Liu M, Zhou J, Liu X, Feng Y, Yang W, et al. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy
efficacy in hepatocellular carcinoma. Gut 2020;69:365-79.
69. Kang N, Gores GJ, Shah VH. Hepatic stellate cells: partners in crime for liver metastases? Hepatology 2011;54:707-13.
70. Amann T, Bataille F, Spruss T, Muhlbauer M, Gabele E, et al. Activated hepatic stellate cells promote tumorigenicity of hepatocellular
carcinoma. Cancer Sci 2009;100:646-53.
71. Neaud V, Faouzi S, Guirouilh J, Le Bail B, Balabaud C, et al. Human hepatic myofibroblasts increase invasiveness of hepatocellular
carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology 1997;26:1458-66.
72. Amin DN, Hida K, Bielenberg DR, Klagsbrun M. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not
ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 2006;66:2173-80.
73. Rolny C, Nilsson I, Magnusson P, Armulik A, Jakobsson L, et al. Platelet-derived growth factor receptor-beta promotes early
endothelial cell differentiation. Blood 2006;108:1877-86.
74. Limmer A, Ohl J, Kurts C, Ljunggren HG, Reiss Y, et al. Efficient presentation of exogenous antigen by liver endothelial cells to
CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med 2000;6:1348-54.
75. Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int 2006;26:1175-86.
76. Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci 2008;103:4-13.
77. Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, et al. Liver failure and defective hepatocyte regeneration in
interleukin-6-deficient mice. Science 1996;274:1379-83.
78. Zhang M, Xu S, Han Y, Cao X. Apoptotic cells attenuate fulminant hepatitis by priming Kupffer cells to produce interleukin-10